Acadian Asset Management
KROS icon

Acadian Asset Management’s Keros Therapeutics KROS Stock Holding History

Acadian Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
115,618
+50,182
+77% +$559K ﹤0.01% 1205
2026
Q1 		$721K Buy
+65,436
New +$1.01M ﹤0.01% 1261
2025
Q2 		– Sell
-147,567
Closed -$1.5M – 1755
2025
Q1 		$1.5M Buy
+147,567
New +$1.71M ﹤0.01% 831
2024
Q4 		– Sell
-2,058
Closed -$119K – 1912
2024
Q3 		$119K Buy
+2,058
New +$102K ﹤0.01% 1531

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management's KROS Position: Q2 2026 in Review

Acadian Asset Management increased its Keros Therapeutics (KROS) stake by 77% in Q2 2026, buying an estimated $559K and bringing the position to 115,618 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

Acadian Asset Management first reported a position in KROS in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.5M in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Acadian Asset Management held 115,618 shares of Keros Therapeutics worth $1.23M as of Q2 2026.
  • Acadian Asset Management bought 50,182 Keros Therapeutics shares in Q2 2026, an estimated $559K.
  • Keros Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1205 holding.
  • Acadian Asset Management first reported a position in Keros Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Acadian Asset Management's Keros Therapeutics position peaked at $1.5M in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.